ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) inParticipants with Relapsed or Refractory Classical Hodgkin?s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
EudraCT number 2020-005609-20
Protocol number MK3475-B68
Sponsor Merck Sharp & Dohme LLC, 126 East Lincoln Ave.,P.O.BOX 2000,Rahway, New Jersey 07065, United States of America
Indications Hemato-oncology
Diagnosis Hodgkin Lymphoma, mediastinal large B-cell lymphoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2021
Date of approval by Institute (SÚKL) 19. 5. 2021
Date of approval by EC 12. 5. 2021
Date of initiation CT in ČR 27. 7. 2021
Date of ending CT in ČR
Sites FN Královské Vinohrady, Interní hematologická klinika, Šrobárova 1150/50, Praha 10, 100 34
FN Brno, Interní hematologická a onkologická klinika, Jihlavská 20, Brno, 625 00
FN Hradec Králové, IV. interní hematologická klinika LF UK, Sokolská 581, Hradec Králové - Nový Hradec Králové, 500 05

‹‹ Back to list